This educational activity is designed to provide our faculty with alternative sources of information and experience on controversial areas in diagnostic pathology that cannot be gleaned from reading the literature or standard textbooks in pathology. There are many areas in pathology where a uniformly acceptable standard has not yet been established. Direct interaction with an expert can provide the pathologist with additional insight into more effective ways to handle the issue.
At the conclusion of this activity, learners will be able to:
Explain the current treatment landscape of CML
Distinguish who is eligible for treatment free remission
Discuss future directions in CML
Ehab Atallah, MD
Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin
All persons in control of content have NO relevant financial relationships to disclose, with the exception of the following, and in accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.
|Ehab Atallah, MD||Pfizer||Speaker|
|Ehab Atallah, MD||Novartis||Speaker|
|Ehab Atallah, MD||Takeda||Speaker|
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.